200 related articles for article (PubMed ID: 29128178)
1. Cost-effectiveness of lobectomy versus genetic testing (Afirma®) for indeterminate thyroid nodules: Considering the costs of surveillance.
Balentine CJ; Vanness DJ; Schneider DF
Surgery; 2018 Jan; 163(1):88-96. PubMed ID: 29128178
[TBL] [Abstract][Full Text] [Related]
2. Molecular Testing Versus Diagnostic Lobectomy in Bethesda III/IV Thyroid Nodules: A Cost-Effectiveness Analysis.
Nicholson KJ; Roberts MS; McCoy KL; Carty SE; Yip L
Thyroid; 2019 Sep; 29(9):1237-1243. PubMed ID: 31407625
[No Abstract] [Full Text] [Related]
3. Cost-Effectiveness of Diagnostic Lobectomy Versus Observation for Thyroid Nodules >4 cm.
Lee L; Mitmaker EJ; Chabot JA; Lee JA; Kuo JH
Thyroid; 2016 Feb; 26(2):271-9. PubMed ID: 26715288
[TBL] [Abstract][Full Text] [Related]
4. Cost analysis of reflexive versus selective molecular testing for indeterminate thyroid nodules.
Hu QL; Schumm MA; Zanocco KA; Yeh MW; Livhits MJ; Wu JX
Surgery; 2022 Jan; 171(1):147-154. PubMed ID: 34284895
[TBL] [Abstract][Full Text] [Related]
5. Thyroid lobectomy as a cost-effective approach in low-risk papillary thyroid cancer versus active surveillance.
Youssef MR; Attia AS; Omar M; Aboueisha M; Freeman MN; Shama M; Kandil E
Surgery; 2022 Jan; 171(1):190-196. PubMed ID: 34384606
[TBL] [Abstract][Full Text] [Related]
6. Cost comparison of initial lobectomy versus fine-needle aspiration for diagnostic workup of thyroid nodules in children.
Baxter KJ; Short HL; Thakore MA; Fisher JG; Rothstein DH; Heiss KF; Raval MV
J Pediatr Surg; 2017 Sep; 52(9):1471-1474. PubMed ID: 28073489
[TBL] [Abstract][Full Text] [Related]
7. Impact of Afirma gene expression classifier on cytopathology diagnosis and rate of thyroidectomy.
Sacks WL; Bose S; Zumsteg ZS; Wong R; Shiao SL; Braunstein GD; Ho AS
Cancer Cytopathol; 2016 Oct; 124(10):722-728. PubMed ID: 27347838
[TBL] [Abstract][Full Text] [Related]
8. Cost impact of molecular testing for indeterminate thyroid nodule fine-needle aspiration biopsies.
Yip L; Farris C; Kabaker AS; Hodak SP; Nikiforova MN; McCoy KL; Stang MT; Smith KJ; Nikiforov YE; Carty SE
J Clin Endocrinol Metab; 2012 Jun; 97(6):1905-12. PubMed ID: 22419727
[TBL] [Abstract][Full Text] [Related]
9. Total Thyroidectomy Versus Lobectomy in Small Nodules Suspicious for Papillary Thyroid Cancer: Cost-Effectiveness Analysis.
Al-Qurayshi Z; Farag M; Shama MA; Ibraheem K; Randolph GW; Kandil E
Laryngoscope; 2020 Dec; 130(12):2922-2926. PubMed ID: 32239764
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of molecular testing for cytologically indeterminate thyroid nodules.
Dharampal N; Smith K; Harvey A; Paschke R; Rudmik L; Chandarana S
J Otolaryngol Head Neck Surg; 2022 Dec; 51(1):46. PubMed ID: 36544210
[TBL] [Abstract][Full Text] [Related]
11. National differences in cost analysis of Afirma Genomic sequencing classifier.
Ronen O; Oichman M
Clin Endocrinol (Oxf); 2021 Apr; 94(4):717-724. PubMed ID: 33349964
[TBL] [Abstract][Full Text] [Related]
12. Selective use of Molecular Testing Based on Sonographic Features of Cytologically Indeterminate Thyroid Nodules: A Decision Analysis.
Zanocco KA; Wang MM; Yeh MW; Livhits MJ
World J Surg; 2020 Feb; 44(2):393-401. PubMed ID: 31538250
[TBL] [Abstract][Full Text] [Related]
13. A Systematic Review of the Methods of Diagnostic Accuracy Studies of the Afirma Gene Expression Classifier.
Duh QY; Busaidy NL; Rahilly-Tierney C; Gharib H; Randolph G
Thyroid; 2017 Oct; 27(10):1215-1222. PubMed ID: 28741442
[TBL] [Abstract][Full Text] [Related]
14. An independent study of a gene expression classifier (Afirma) in the evaluation of cytologically indeterminate thyroid nodules.
McIver B; Castro MR; Morris JC; Bernet V; Smallridge R; Henry M; Kosok L; Reddi H
J Clin Endocrinol Metab; 2014 Nov; 99(11):4069-77. PubMed ID: 24780044
[TBL] [Abstract][Full Text] [Related]
15. Molecular Testing for Thyroid Nodules of Indeterminate Cytology: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2022; 22(2):1-111. PubMed ID: 35591972
[TBL] [Abstract][Full Text] [Related]
16. Surgical utility of Afirma: effects of high cancer prevalence and oncocytic cell types in patients with indeterminate thyroid cytology.
Harrell RM; Bimston DN
Endocr Pract; 2014 Apr; 20(4):364-9. PubMed ID: 24246351
[TBL] [Abstract][Full Text] [Related]
17. The first Canadian experience with the Afirma® gene expression classifier test.
Kay-Rivest E; Tibbo J; Bouhabel S; Tamilia M; Leboeuf R; Forest VI; Hier MP; Savoury L; Payne RJ
J Otolaryngol Head Neck Surg; 2017 Apr; 46(1):25. PubMed ID: 28372589
[TBL] [Abstract][Full Text] [Related]
18. Analysis of an institutional protocol for thyroid lobectomy: Utility of routine intraoperative frozen section and expedited (overnight) pathology.
Berg RW; Yen TW; Evans DB; Hunt B; Quiroz FA; Wilson SD; Wang TS
Surgery; 2016 Feb; 159(2):512-7. PubMed ID: 26361834
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of a novel molecular test for cytologically indeterminate thyroid nodules.
Li H; Robinson KA; Anton B; Saldanha IJ; Ladenson PW
J Clin Endocrinol Metab; 2011 Nov; 96(11):E1719-26. PubMed ID: 21865367
[TBL] [Abstract][Full Text] [Related]
20. Lobectomy is a more Cost-Effective Option than Total Thyroidectomy for 1 to 4 cm Papillary Thyroid Carcinoma that do not Possess Clinically Recognizable High-Risk Features.
Lang BH; Wong CKH
Ann Surg Oncol; 2016 Oct; 23(11):3641-3652. PubMed ID: 27221359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
